news
Cancer immunotherapy adapted to treat COVID-19 variants
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
List view / Grid view
In Vitro
news
SARS-CoV-2 blocked by antiviral substances discovered in South Korean plants
South Korean researchers identified two saponins there were highly effective in blocking the ability of SARS-CoV-2 variants to enter cells.
article
Drug discovery for COPD treatments
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
news
In vitro hair follicle model grown in culture
Scientists have developed a new strategy to generate hair follicles in vitro with potential useful applications for treating hair loss, animal testing and drug screening.
article
Right model, right complexity: using in vitro human disease cell models in drug discovery
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
news
Study reveals how tau impairs communication between neurons in Alzheimer’s
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
article
Drug Target Review Neuroscience ebook 2022
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
webinar
CHO targeted integration platform for accelerated antibody development
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
news
Newly identified compound reduces potency of Shiga toxin
Scientists have identified a molecule that can bind to a lethal subtype of the bacterial Shiga toxin, suppressing its deadly effects.
webinar
Comprehensive in vitro approach to evaluate transporter-mediated drug interactions in drug discovery
4 July 2022 | By Eurofins Discovery
In this on-demand webinar, an assay strategy to assess transport-mediated drug interactions that complies with regulations is examined.
article
The promise of cryo-electron tomography
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Michael Grange, Tomography Group Leader from the Rosalind Franklin Institute (RFI), UK about the advantages of using cryo-electron tomography imaging.
whitepaper
Product hub: A reproducible and scalable Huntington’s disease human cell model
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
article
Miniaturising organoid drug screens using nanofibrillar cellulose hydrogels
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…
article
Drug Target Review Stem Cells ebook
This ebook includes a piece by Daniel Morales- Mantilla, Dr Robin Parihar and Dr Katherine King, from Baylor College of Medicine, on a stem and progenitor cell infusion to improve the survival of mice from sepsis as well as an article by Dr Karen Litwa, East Carolina University, that explores…
webinar
Leveraging the E3scanTM technology platform for next-generation targeted protein degradation
6 May 2022 | By Eurofins Discovery
Watch our free on-demand webinar to learn how to accelerate screening and Structure Activity Relationship (SAR) analysis in the targeted protein degradation (TPD) drug discovery field.
